Eli Lilly Insilico Deal: $2.75B Bet on AI-Designed Oral Drugs

What happened

Eli Lilly has signed a licensing and research agreement with Insilico Medicine, the Hong Kong-listed developer that uses generative AI to discover drugs. The deal could be worth up to $2.75 billion once milestone payments are counted. 1 Insilico gets $115 million upfront. It is also eligible for development, regulatory and commercial milestones, plus tiered royalties on future sales. 24

The deal has two parts. First, Lilly receives an exclusive worldwide licence to develop, manufacture and sell a set of Insilico's preclinical oral drug candidates in selected disease areas. 12 Second, Lilly will use Insilico's Pharma.AI platform, which runs from target discovery through compound design, to pursue more research programmes aimed at targets Lilly chooses. 2

The timing is reported slightly differently. Reuters described the announcement as coming on Sunday, March 29. 1 The South China Morning Post said the agreement was announced on Monday. 4 The difference likely reflects time zones and the Hong Kong trading calendar rather than any real disagreement.

The undisclosed disease areas

The most notable gap in the announcement is what the drugs actually treat. Neither company named the disease areas. 2 The South China Morning Post reported that contract restrictions kept the specific drugs and indications confidential. 4 Insilico founder and CEO Alex Zhavoronkov offered some description of the programmes, but no source names a specific target or indication.

Any claim that the deal centres on a particular drug class goes beyond what has been made public. Lilly's commercial strength in metabolic disease makes it tempting to assume the oral candidates are aimed there. Based on available reporting, that remains an assumption, not a fact. Analysts should treat disease-area claims carefully until either company says more.

How the market reacted

Investors responded quickly. Insilico shares rose as much as 15% at Monday's open, the stock's strongest intraday rally in almost two months. 3 The early jump took shares to HK$65.75. Most of that gain faded during the session, and the stock closed at HK$58.70, up 2.6%. 4

The partial retreat suggests some caution. The headline figure is large, but most of it depends on milestones. The guaranteed cash is the $115 million upfront, a small share of the potential $2.75 billion. That structure is common in biotech licensing, where reported totals assume every programme succeeds.

Insilico came to the deal with momentum. It listed in Hong Kong in December, and its shares were up more than 50% year to date before the announcement. 5 Lilly, for its part, recently became the first drugmaker to reach $1 trillion in market value. 1

Why Insilico

The two companies have worked together since 2023, so this deal expands an existing relationship. 25 Insilico has stronger evidence behind its approach than many AI-drug startups. Its lead compound, rentosertib, is described as the first drug where generative AI found both the biological target and the molecule. It reported positive Phase I results. 2 Zhavoronkov told CNBC the company has produced at least 28 drugs with generative AI tools, and nearly half are already in clinical testing. 5

Zhavoronkov also said Lilly has a competitive edge in some aspects of AI. 5 That fits the platform part of the deal: Lilly is buying access to Insilico's discovery engine, not only a few molecules. Insilico also runs an automated lab, Life Star2, which reflects its push to combine computational design with robotic experiments. 4

The sources describe the company's base slightly differently. Most call it Hong Kong-based. 35 The South China Morning Post describes Insilico as US-headquartered and Hong Kong-listed. 4 The company is 12 years old. 4

The bigger picture

Drugmakers are increasingly using AI to speed up research and development. They are betting that modelling tools and automated labs can improve efficiency across their pipelines. 1 Reuters also links the trend to the US Food and Drug Administration's push to reduce animal testing. 1 Computational and automated methods could help fill that gap.

My reading is that this deal is a meaningful validation of Insilico's model, but not yet proof that AI-designed drugs succeed commercially. Lilly is paying a modest upfront sum for preclinical assets plus platform access, while keeping the option to pay much more if the programmes work. That is a hedged bet, not a blank cheque. The real test will come as these candidates enter human trials. That is also when the disease areas are likely to be disclosed, and when it will become clear whether Lilly's interest matches its existing franchises or extends beyond them.